We did not found any significant association between XPC Val499Arg polymorphism and gastric cancer risk when all the eligible studies were pooled into the meta-analysis (Val/Val vs. Ala/Ala: OR = 0.861, 95% CI = 0.632–1.172, P = 0.341; Val/Ala vs. Ala/Ala: OR = 0.815, 95% CI = 0.611–1.089, P = 0.167; Val/Val + Val/Ala vs. Ala/Ala: OR = 0.823, 95% CI = 0.630–1.076, P = 0.155; Val/Val vs. Val/Ala + Ala/Ala: OR = 0.947, 95% CI = 0.703-1.274, P = 0.717). The gene discussed is XPC; the disease is gastric cancer.